Nervous System Channel
Related Channels

Orally Disintegrating Selegiline Dosage

The orally disintegrating selegiline dosage your healthcare provider prescribes will depend on several factors, such as how you respond to the medication and other medications you are taking. Typically, the recommended starting dose is 1.25 mg, taken once daily. If necessary, your healthcare provider may increase your orally disintegrating selegiline dose up to a maximum dosage of 2.5 mg daily.

Orally Disintegrating Selegiline Dosage: An Introduction

The dose of orally disintegrating selegiline (Zelapar®) your healthcare provider recommends will vary, depending on a number of factors, including:
  • How you respond to orally disintegrating selegiline
  • Other medications you are taking
  • Other medical conditions you may have.
As is always the case, do not adjust your dose unless your healthcare provider specifically instructs you to do so.

Orally Disintegrating Selegiline Dosage for Parkinson's Disease

The recommended starting dose of orally disintegrating selegiline for Parkinson's disease is 1.25 mg, taken once daily in the morning before breakfast. After at least six weeks, if necessary, your healthcare provider may increase your dose up to 2.5 mg (two 1.25-mg tablets), taken once daily in the morning before breakfast. In no case should the dose be increased more than 2.5 mg per day.
Orally disintegrating selegiline is approved for use in combination with levodopa-carbidopa medications, such as Sinemet®, Sinemet CR®, or Parcopa®. Many people will need to use a lower carbidopa-levodopa dosage, especially if side effects occur. Your healthcare provider will determine when (and if) you need to lower your carbidopa-levodopa dosage.
Because the liver and kidneys help remove orally disintegrating selegiline from the body, people with liver or kidney problems may need a lower orally disintegrating selegiline dosage, although specific recommendations are not available.
5 Questions to Ask Your Doctor About ED

Selegiline for Parkinson's Disease

Referring Pages:
Terms of Use
Advertise with Us
Contact Us
About eMedTV
Privacy Policy
Copyright © 2006-2018 Clinaero, Inc.
eMedTV serves only as an informational resource. This site does not dispense medical advice or advice of any kind. Site users seeking medical advice about their specific situation should consult with their own physician. Click Terms of Use for more information.